Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    19451549 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Suspended T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Conditions: Metastatic Cancer That Express the MAGE-A3-HLA A01 Antigen;   Metastatic Melanoma That Express the MAGE-A3-HLA A01 Antigen;   Metastatic Cancer
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR

Study has passed its completion date and status has not been verified in more than two years.